📢EMA starts rolling review of Eli Lilly antibodies bamlanivimab and etesemivab for COVID-19

EMA’s human medicines committee (CHMP) has started a rolling review of the Eli Lilly antibodies bamlanivimab and etesemivab for #COVID19. The decision to start the rolling review is based on preliminary results from two studies - one looking at the ability of the medicines to treat COVID-19 when combined, the other one when bamlanivimab is used alone.

  More information details>>>>